Maymetsi (Metformin Hydrochloride, Sitagliptin)

Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, while sitagliptin blocks the enzyme dipeptidyl‑peptidase‑4, prolonging the activity of incretin hormones that stimulate insulin release and suppress glucagon in a glucose‑dependent manner.

The prescribed dose of Maymetsi is determined by the treating physician based on individual patient factors such as renal function, current glycaemic control, and concomitant medications. The prescriber will select the appropriate strength and dosing schedule.

Safety of Maymetsi in pregnancy or lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Maymetsi product page at gnhindia.com, providing the required quantity and your institutional credentials. GNH India works with hospitals, pharmacies and procurement teams worldwide, then replies with pricing, availability, shipping details and any necessary import documentation.

Compared with metformin monotherapy, Maymetsi adds sitagliptin to provide additional glucose‑lowering effect without the weight gain associated with some sulfonylureas. Unlike insulin, it is administered orally and carries a lower risk of hypoglycaemia when used alone.

Maymetsi tablets should be stored at ambient temperature, preferably below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

Maymetsi is taken orally, usually once daily with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water; it should not be crushed, chewed, or split unless specifically advised.

The most serious adverse events include lactic acidosis related to metformin, especially in patients with renal impairment, and rare cases of pancreatitis or severe hypersensitivity reactions linked to sitagliptin. Prompt medical attention is required if symptoms such as unexplained abdominal pain, rapid breathing, or swelling occur.

Maymetsi is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin, sitagliptin, or any component of the formulation, and in individuals with a history of lactic acidosis. It should also be avoided in patients receiving iodinated contrast agents until renal function is reassessed.